The results of the study demonstrated tolerable toxicities, as well as better PFS [12.9 versus 9.2 months, HR, 0.75; 95% confidence interval (CI): 0.53–1.05, p < 0.05] of double-dose icotinib in NSCLC patients with the EGFR exon 21 L858R mutation when compared with routine dose (11). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.